Compare

Nektar Therapeutics vs Aytu Biopharma, Inc vs Ocular Therapeutix, Inc vs Lexicon Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearNektar Therapeutics
NKTR
Aytu Biopharma, Inc
AYTU
Ocular Therapeutix, Inc
OCUL
Lexicon Pharmaceuticals, Inc.
LXRX
Year ended2025-12-312026-06-302025-12-312025-12-31
Revenue$55.23M$57.57M$51.95M$49.80M
Revenue growth (YoY)-43.9%-13.3%-18.5%+60.2%
Gross marginn/a64.0%87.3% (computed)n/a
Operating margin-253.7%-14.4%-519.8%-98.2%
Net margin-297.1%-24.8%-511.9%-101.1%
Net income-$164.08M-$14.25M-$265.94M-$50.34M
EPS (Diluted)-$9.73n/a-$1.42-$0.14
Operating cash flow-$208.51M$3.28M-$204.88M-$67.85M
Free cash flow-$208.68M$3.25M-$216.89M-$67.85M
Cash & equivalents$15.12M$26.31M$737.06M$34.33M
Total assets$280.41M$105.01M$808.06M$184.99M
Total liabilities$190.57Mn/a$153.75M$77.45M
Shareholders' equity$89.83M$35.27M$654.31M$107.54M
Return on year-end equity-182.6%-40.4%-40.6%-46.8%
Shares outstanding20.38M10.73M215.93M365.85M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearNektar TherapeuticsAytu Biopharma, IncOcular Therapeutix, IncLexicon Pharmaceuticals, Inc.
Latest$55.23M
Ended 2025-12-31
$57.57M
Ended 2026-06-30
$51.95M
Ended 2025-12-31
$49.80M
Ended 2025-12-31
1 year earlier$98.43M
Ended 2024-12-31
$66.38M
Ended 2025-06-30
$63.72M
Ended 2024-12-31
$31.08M
Ended 2024-12-31
2 years earlier$90.12M
Ended 2023-12-31
$65.18M
Ended 2024-06-30
$58.44M
Ended 2023-12-31
$1.20M
Ended 2023-12-31
3 years earlier$92.06M
Ended 2022-12-31
$107.40M
Ended 2023-06-30
$51.49M
Ended 2022-12-31
$139.0K
Ended 2022-12-31
4 years earlier$101.91M
Ended 2021-12-31
$96.67M
Ended 2022-06-30
$43.52M
Ended 2021-12-31
$298.0K
Ended 2021-12-31